Aug. 16, 2025 at 12:39 PM ET6 min read

Oscar Health Raises FY25 Revenue Projection, Eyes Profitability

Tim BohenAvatar
Written by Tim Bohen Reviewed by Ben Sturgill Fact-checked by Ellis Hobbs

Oscar Health Inc.’s stocks have been trading up by 7.63 percent, likely fueled by positive public sentiment and promising news.

Recent Updates and Key Highlights

  • The healthcare insurer raised its full-year 2025 revenue expectations to a range of $12.0B to $12.2B, surpassing previous forecasts of $11.2B to $11.3B.
  • Financial forecasts reveal operational losses for FY25 to be contained within a tighter range of ($300K) to ($200K), showcasing fiscal discipline.
  • Following a solid reaffirmation, the projected FY25 revenue aligns closely with market predictions, anticipating a steadily bullish trajectory.
  • Second-quarter results reflected heightened revenue yet also a broader loss, signaling a strategic focus on the individual market.
  • Despite lowered price targets by some analysts, a return to profitability remains forecasted for 2026, echoing long-term optimism.

Healthcare industry expert:

Analyst sentiment – positive

Oscar Health (OSCR) is in a precarious market position, struggling with significant profitability challenges. The company reports negative EBIT and pre-tax profit margins at -0.2% and -6% respectively, indicating operational inefficiencies and elevated costs. Revenue is considerable at $9.17 billion, highlighting a growth trajectory, but it’s overshadowed by a net income loss of $228 million. Concerning financial signals include negative returns on equity (-26.44%) and assets (-6.74%), challenging Oscar Health’s capacity to generate adequate returns on its largescale operations. Despite a robust cash position and no long-term debt, its high leverage ratio of 5.5 further raises concerns about financial stability.

The technical analysis of Oscar Health points to a positive price trend. Starting from an open of $14.98 on 250812 and closing at $15.83 on 250815, the stock exhibits steady upward movement, indicating a strong bullish sentiment. The breakout above $15.64 is noteworthy, suggesting the emergence of buyer interest and increased momentum. Investors should focus on key support at $15.08 and resistance near $15.85, considering possible gains if the stock breaks decisively above this upper level. Volume analysis shows supporting strength in recent buying activity, hinting at sustained interest among market participants.

Recent developments paint a mixed but cautiously optimistic outlook for Oscar Health. It has revised its FY25 revenue guidance upwards to between $12.0-$12.2 billion, surpassing prior estimates and suggesting potential growth in market share. Although Q2 results missed analysts’ expectations with revenues of $2.86 billion and substantial losses, Oscar anticipates narrower operational losses and improved EBITDA metrics. The commitment to profitability targets by 2026, coupled with raised annual guidance, positions Oscar Health favourably against broader healthcare benchmarks. Despite analyst downgrades, the affirmed FY25 targets and strategic focus enhance its outlook. Current resistance at $16 could act as a milestone if breached successfully, while $13 serves as significant support.

Candlestick Chart

More Breaking News

Weekly Update Aug 11 – Aug 15, 2025: On Saturday, August 16, 2025 Oscar Health Inc. stock [NYSE: OSCR] is trending up by 7.63%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Oscar Health’s recent financial reports show mixed performance, pointing to a dynamic shift in strategy and market position. The company locked in a net revenue of $2.86 billion for Q2 2025, which narrowly missed analyst projections of $2.91 billion. This variation underlines a noteworthy expansion yet highlights areas for efficiency improvements—especially given an anticipated net loss surpassing the $200 million mark for the quarter.

Despite the widened loss, revenue growth presents a bright spot. With the elevated FY25 forecast now at $12.0B-$12.2B, the company’s strategy seems bullish, aiming to capture market momentum. Furthermore, key financial metrics shed light on operational challenges, such as a profit margin contraction and price-to-sales evaluation at 0.36, suggesting modest investor confidence tempered by ongoing fiscal adjustments.

The effort to curb operational expenditures is apparent as the company contained projected EBITDA losses tighter than initially forecast. Revenue per share sits robustly at over $41, further speaking to underlying strength despite near-term setbacks.

Conclusion

Oscar Health’s articulated focus on revenue growth against a backdrop of controlled operational losses spells a calculated approach to broader market expansion. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” This mindset of thorough preparation aligns perfectly with Oscar Health’s strategy, ensuring that by the time market decisions need to be acted upon, the company is ready and informed. The pathway to long-term profitability, with strategic individual market commitment, positions the company as a viable player in the healthcare arena. Looking forward, maintaining financial discipline and operational improvements will be pivotal to realizing ambitious revenue targets and ultimate profitability milestones.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.